loader
Please Wait
Applying Filters...

Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Drug Master Files (DMF) for 23157 Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website

    Client Virtual Booth
    Menu

    Biovet AD

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Aspen API. More than just an API.

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 Biovet AD (1)

    filter

    01 TESTOSTERONE (1)

    filter

    01 Bulgaria (1)

    filter

    01 Inactive (1)

    filter

    01 Blank (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    BIOVET JOINT STOCK CO

    Contact Supplier
    • FDA
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag Bulgaria
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    TESTOSTERONE

    PDF Supplier PDF
    URL Supplier Web Content
    23157
    Inactive
    2009-09-30
    N/A
    II
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    Looking for Drug Master Files (DMF) for 23157 of Biovet Joint Stock Co

    Looking for Drug Master Files (DMF) for 23157 of Biovet Joint Stock Co 1

    20

    Biovet Joint Stock Co, based in Bulgaria, is a pharmaceutical company that stands out with its certifications from FDA.

    One of their notable products is TESTOSTERONE, with a corresponding US DMF Number 23157.

    Remarkably, this DMF maintains an Inactive status since its submission on September 30, 2009, highlighting commitment to regulatory compliance.

    Post Enquiry
    POST ENQUIRY